인플루엔자 진단 시장 규모는 2024년에는 8억 4,000만 달러에서 2031년에는 15억 6,000만 달러에 달할 것으로 예상되며, 2024-2031년 연평균 9.00%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 일반적으로 독감으로 알려진 인플루엔자는 인플루엔자 바이러스에 의해 유발되는 감염성 질환입니다. 인플루엔자의 식별 및 진단을 위해 다양한 기존 기술 및 분자진단 기술이 사용되고 있습니다. 역전사 중합효소 연쇄반응과 실시간 분자 검사는 독감 유전 물질을 검출할 수 있습니다. 인플루엔자 신속 진단 검사는 계속 발전하고 있으며, 빠른 결과와 샘플 채취의 용이성으로 인해 이 방법은 진단에 효과적입니다. 독감 유행 증가, 특정 진단 검사를 통한 조기 발견에 대한 인식 증가, 중앙 집중식 검사실에서 분산형 현장 검사로의 전환 등의 요인으로 인해 세계 독감 진단 시장의 성장이 촉진될 것으로 예상됩니다.
또한 만성질환의 유병률 증가, 노인 인구 증가, 독감 모니터링을 위한 정부 구상 증가, 기술적으로 진보된 독감 진단 검사의 개발로 인해 독감 진단에 대한 수요는 증가할 것으로 보입니다.
현장 진료 기술과 독감 검사의 통합 등 기술적으로 진보된 새로운 독감 진단 검사는 노인 인구의 감시 과정을 촉진할 것으로 예상됩니다. 또한 현장 진료 기술은 의료 접근성이 제한적인 아시아태평양의 농촌 지역에서 독감 검사를 증가시킬 것으로 예상됩니다.
그러나 검사 및 장비 개발 비용이 시장 개척의 걸림돌이 될 수 있습니다. 원재료의 가용성 및 접근성의 제약이 제품의 총비용을 상승시킵니다. 높은 제조 비용의 부담은 높은 가격으로 최종사용자에게 전가됩니다.
독감 부담 증가:
전 세계에서 유행하는 계절성 독감은 심각한 질병, 입원 및 사망을 유발하여 신속하고 정확한 진단 기술의 필요성을 강조하고 있습니다. 이러한 툴은 치료법을 결정하고 효과적인 관리 조치를 시행하는 데 필수적입니다.
건강관리에 대한 인식 증가:
독감과 그 영향에 대한 대중의 인식이 높아짐에 따라 신속하고 간편한 진단 검사에 대한 수요가 증가하고 있습니다. 이러한 발전은 헬스케어에 대한 적극적인 태도를 나타내며, 사람들은 쉽게 이용할 수 있는 진단 솔루션을 원하고 있습니다.
기술의 진보 :
고속 분자 분석, 현장 검사, 멀티플렉스 분석과 같은 새로운 기술이 인플루엔자 진단에 변화를 가져오고 있습니다. 이러한 발전으로 속도와 정확도가 향상되고 동시에 많은 인플루엔자 균주를 식별할 수 있게 되어 진단 능력이 향상되고 있습니다.
조기발견과 치료의 중요성:
인플루엔자의 조기 치료와 합병증 예방을 위해서는 조기 발견과 조기 치료가 중요합니다. 신속한 진단 검사를 통해 항바이러스제를 통한 조기 치료가 가능해져 환자의 예후를 개선하고 의료비용을 절감할 수 있습니다.
확대되는 노령 인구
전 세계 인구가 고령화됨에 따라 노인들은 특히 독감 관련 문제를 일으키기 쉽습니다. 이러한 인구 통계학적 변화는 노인들 수요에 맞는 신뢰할 수 있고 간편하게 이용할 수 있는 진단 검사의 중요성을 강조하고 있습니다.
생물학적 위협에 대한 대비 :
인플루엔자 바이러스는 대유행을 일으킬 수 있으므로 생물학적 위협에 대한 대비 및 대응 활동에는 신속하고 정확한 진단 기술이 필요합니다. 효과적인 진단법은 발병을 억제하고 피해를 최소화하기 위해 필수적입니다.
정부의 구상과 상환 정책 :
일부 정부는 독감 예방 접종 및 진단을 촉진하기 위해 공중 보건 구상을 시작했습니다. 또한 독감 진단 검사에 대한 유리한 지불 규정은 접근성을 높이고 이러한 중요한 장비의 보급을 촉진하는 데 중요한 역할을 합니다.
주요 과제
검사 민감도 및 특이도 편차 :
특히 신속검사의 경우 검사 성능에 편차가 있으며, 인플루엔자와 다른 호흡기 감염증의 감별이 제대로 이루어지지 않아 오진이나 부적절한 치료 권고로 이어질 수 있습니다.
고급 검사는 비용이 많이 듭니다.
분자 분석과 같은 첨단 기술은 더 높은 정확도를 제공하지만 그만큼 비용이 많이 들기 때문에 특히 의료 예산이 한정된 자원이 부족한 지역에서는 접근성이 제한됩니다.
표준화 부족:
성능 특성이 다른 여러 가지 독감 진단 검사가 널리 보급되어 검사 결과의 해석과 비교가 복잡해져 의료진에게 불확실성을 초래하고 환자의 효과적인 치료 방침을 결정하는 데 어려움을 겪고 있습니다.
원격지에서의 제한된 가용성:
외딴 지역이나 저소득 지역에서는 고급 진단 검사에 대한 접근이 제한되어 진단과 치료가 지연되고, 특히 고급 검사 기능을 갖춘 의료 시설에 대한 접근 장벽에 직면한 사회적 약자의 경우 이러한 경향이 더욱 강합니다.
숙련된 인재의 부족:
최신 독감 진단 검사 중 일부는 올바르게 조작하고 해석하기 위해 특별한 훈련과 기술이 필요한 경우가 있습니다. 이러한 검사를 사용할 수 있는 경우에도 특정 지역에서는 유능한 인력이 부족하여 효과적으로 사용할 수 없습니다.
진료비 문제 :
인플루엔자 진단에 대한 불충분한 상환 규정으로 인해 의료 서비스 프로바이더가 새로운 기술을 채택하지 못하여 전체 시장의 성장과 개선된 테스트의 사용을 제한할 수 있습니다.
위양성 및 위음성 :
일부 검사에서 위양성 또는 위음성 결과가 나올 수 있으며, 이로 인해 불필요한 치료, 자원 낭비, 환자의 불안감을 유발하고 검사 방법의 효과와 비용 효율성을 저해할 수 있습니다.
진화하는 바이러스 균주 :
인플루엔자 바이러스는 끊임없이 변화하고 있으며, 진단법을 성공적으로 유지하기 위해서는 지속적인 업데이트와 변경이 필요합니다. 새로운 바이러스 균주의 도입은 정확하고 신뢰할 수 있는 진단 시스템을 유지하는 데 있으며, 진단 약품 제조업체의 비용과 장애물을 증가시킬 수 있습니다.
주요 동향
신속한 진단 검사 채택:
인플루엔자 신속진단검사(RIDT)는 편의성, 신속성, 사용의 용이성으로 인해 진료 시점에 신속한 치료 방침을 결정할 수 있으며, 점점 더 널리 보급되고 있습니다.
멀티플렉스 분석의 출현:
멀티플렉스 어세이는 인플루엔자 바이러스, RSV 등 다수의 호흡기 감염증을 한 번의 검사로 검출할 수 있으며, 효율성이 향상되고 여러 번 검사할 필요가 없어져 보급이 확산되고 있습니다.
POCT(Point-of-Care Test)에 대한 집중도:
업계는 독감 진단을 위한 POCT(Point-of-Care) 검사 솔루션 개발로 전환하고 있으며, 이를 통해 병원, 약국, 가정 등 다양한 장소에서 휴대가 가능하고 사용하기 편리한 옵션을 제공할 수 있게 되었습니다.
원격의료 플랫폼과의 통합 :
독감 진단 검사는 원격의료 플랫폼과 빠르게 연결되고 있으며, 원격 진단 및 진료가 가능해짐에 따라 특히 소외된 지역의 의료 접근성을 향상시킬 수 있습니다.
분자진단의 기술적 진보 :
기술의 발전과 함께 독감 진단을 위한 보다 민감하고 특이적인 분자 분석법이 개발되고 있으며, 이는 서로 다른 독감 균주를 구별할 수 있게 하여 표적 치료 전략과 백신 개발에 도움을 주고 있습니다.
인공지능의 통합:
인공지능(AI) 알고리즘이 독감 진단에 통합되고, 진단 검사 데이터 분석을 통해 정확도 향상, 신종 균주 식별, 유행 예측이 가능해졌습니다.
재택 검사의 중요성:
COVID-19 팬데믹으로 인해 재택 진단 검사에 대한 수요가 증가하고 있으며, 사용하기 쉬운 자가 진단 키트의 발전으로 독감 진단에도 비슷한 추세가 예상됩니다.
Influenza Diagnostics Market size was valued at USD 0.84 Billion in 2024 and is projected to reach USD 1.56 Billion by 2031 , growing at a CAGR of 9.00% from 2024 to 2031. Influenza, commonly known as the flu, is an infection caused by the influenza virus. A variety of traditional and molecular diagnostic technologies are used to identify and diagnose influenza. Reverse transcription-polymerase chain reaction and real-time molecular testing allows the detection of influenza genetic material. Continued advances in rapid influenza diagnostic testing have made this method effective for diagnosis due to its rapid results and ease of sample collection. Factors such as the increasing prevalence of influenza, increasing awareness of early detection using specific diagnostic tests, and a shift in focus from centralized laboratories to decentralized point-of-care testing are expected to drive the growth of the global influenza diagnostics market.
Additionally, due to the increasing prevalence of chronic diseases, the growing geriatric population, increasing government initiatives to monitor influenza, and the development of technologically advanced diagnostic tests for influenza, the demand for influenza diagnostics is likely to increase.
Emerging technologically advanced influenza diagnostic tests, including integration of point-of-care technology and influenza testing, are expected to facilitate the surveillance process in the geriatric population. In addition, point-of-care technology is expected to increase influenza testing in rural areas of the Asia-Pacific region, where access to health care is limited.
However, the cost of test and equipment development may hamper the market growth. Raw material availability and accessibility constraints increase the total cost of the product. The burden of high production costs is passed on to end users at high prices.
The key market dynamics that are shaping the global influenza diagnostics market include:
Escalating Burden of Influenza:
Global seasonal influenza outbreaks cause significant sickness, hospitalizations, and deaths, emphasizing the need for rapid and precise diagnostic techniques. These tools are critical for making treatment decisions and carrying out effective management measures.
Increased Healthcare Awareness:
As the public becomes more aware of influenza and its repercussions, there is a greater demand for quick and simple diagnostic testing. This development represents a proactive attitude to health management, with people seeking easily accessible diagnostic solutions.
Advancements in Technology:
Novel technologies including as fast molecular assays, point-of-care tests, and multiplex assays are transforming influenza diagnostics. These advancements improve speed, accuracy, and the ability to identify many influenza strains at the same time, hence increasing diagnostic capabilities.
Emphasis on Early Detection and Treatment:
Early detection and treatment are crucial for early treatment and preventing complications from influenza. Rapid diagnostic tests allow for early intervention with antiviral drugs, which improves patient outcomes and reduces healthcare costs.
Expanding Geriatric Population
: As the world population ages, the elderly are especially vulnerable to influenza-related problems. This demographic transition highlights the importance of reliable and conveniently accessible diagnostic testing adapted to the demands of older persons.
Biothreat Preparedness:
Influenza viruses have the potential to cause pandemics, hence rapid and accurate diagnostic technologies are required for biothreat preparedness and response operations. Effective diagnostics are critical for limiting outbreaks and minimizing their damage.
Government Initiatives and Reimbursement Policies:
Several governments are launching public health initiatives to promote influenza vaccination and diagnosis. Furthermore, favorable payment rules for influenza diagnostic tests play an important role in increasing accessibility and encouraging widespread usage of these critical instruments.
Key Challenges:
Variability in Test Sensitivity and Specificity:
Inconsistencies in test performance, especially with quick testing, can lead to incorrect discrimination between influenza and other respiratory infections, resulting in misdiagnosis and poor treatment recommendations.
High Cost of Advanced Tests:
Advanced technologies such as molecular assays provide greater precision but come at a higher cost, limiting access, particularly in resource-constrained regions with restricted healthcare budgets.
Lack of Standardization:
The prevalence of several influenza diagnostic tests with differing performance characteristics complicates interpreting and comparing results across tests, causing uncertainty for healthcare practitioners and impeding effective patient treatment decisions.
Limited Availability in Remote Areas:
Access to advanced diagnostic tests is limited in distant or low-income areas, delaying diagnosis and treatment, especially for vulnerable groups that face barriers to accessing healthcare facilities with advanced testing capabilities.
Limited Skilled Personnel:
Certain modern influenza diagnostic tests necessitate specific training and skills to operate and interpret correctly. Even when these tests are available, a lack of competent workers in certain places prevents them from being used effectively.
Reimbursement Issues:
Inadequate reimbursement regulations for influenza diagnostics may prevent healthcare providers from adopting newer technologies, limiting overall market growth and the availability of improved tests.
False Positives and Negatives:
Despite improvements, some tests continue to provide false positive or negative results, resulting in wasteful treatments, resource waste, and patient worry, compromising the effectiveness and cost-efficiency of testing methodologies.
Evolving Viral Strains:
Influenza viruses are constantly changing, demanding ongoing updates and changes to diagnostic procedures in order to remain successful. The introduction of novel virus strains may result in increased expenditures and hurdles for diagnostic manufacturers in maintaining accurate and trustworthy diagnostic systems.
Key Trends:
Adoption of Rapid Diagnostic Tests:
Rapid influenza diagnostic tests (RIDTs) are becoming increasingly popular because to their convenience, speed, and ease of use, allowing for swift treatment decisions at the point of care.
Emergence of Multiplex Assays:
Multiplex assays are becoming popular because they may detect numerous respiratory infections, such as influenza viruses and RSV, in a single test, increasing efficiency and eliminating the need for multiple tests.
Focus on Point-of-Care Testing (POCT):
The industry is shifting toward developing point-of-care testing (POCT) solutions for influenza diagnostics, which will provide portable and user-friendly options for a variety of locations, including clinics, pharmacies, and homes.
Integration with Telehealth Platforms:
Influenza diagnostic tests are rapidly being connected with telehealth platforms, allowing for remote diagnosis and consultation, hence enhancing healthcare access, particularly in underprivileged areas.
Technological Advances in Molecular Diagnostics:
As technology advances, more sensitive and specific molecular assays for influenza diagnosis are being developed, allowing for differentiation between different influenza strains and aiding in targeted treatment strategies and vaccine development.
Integration of Artificial Intelligence:
Artificial intelligence (AI) algorithms are being integrated into influenza diagnostics to improve accuracy, identify new strains, and anticipate epidemics by using diagnostic test data analysis.
Growing Emphasis on Home-Based Testing:
The COVID-19 pandemic has increased demand for home-based diagnostic tests, and similar trends are projected for influenza diagnostics, as advances in user-friendly self-testing kits become more widely available.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Here is a more detailed regional analysis of the global influenza diagnostics market:
North America
North America is significantly dominating the influenza diagnostics market and is expected to continue its growth throughout the forecast period, owing to several variables.
North America has a well-developed healthcare infrastructure that includes cutting-edge medical facilities, advanced laboratories, and a qualified workforce. This infrastructure facilitates the effective diagnosis and management of influenza patients, which contributes to the region's market leadership.
The region is home to leading pharmaceutical businesses, diagnostic manufacturers, and research organizations focused on improving influenza diagnostics. Ongoing research and development activities are aimed at inventing new diagnostic technologies, improving test accuracy, and increasing testing accessibility, thereby cementing North America's position as a dominating market participant.
North America routinely devotes a high portion of its GDP to healthcare spending, allowing for major investment in healthcare technologies such as influenza diagnostics. The availability of large financial resources encourages the use of modern diagnostic tests and promotes market expansion in the region.
Each year, North America suffers significant seasonal influenza outbreaks, which cause a significant illness burden and public health impact. The incidence of influenza increases the demand for speedy and accurate diagnostic tests to guide treatment decisions, implement control measures, and limit disease spread, supporting the region's dominant position in the influenza diagnostics market.
Many of the world's largest influenza diagnostic firms, including those that make fast tests, molecular assays, and point-of-care devices, have their headquarters or a significant presence in North America. These companies use the region's superior infrastructure, research capabilities, and regulatory framework to develop and deliver breakthrough diagnostic solutions, reinforcing North America's market leadership.
Asia Pacific
Asia Pacific is anticipated to be the fastest-growing region in the influenza diagnostics The Asia Pacific area is undergoing rapid economic expansion, which has coincided with advancements in healthcare infrastructure and access to medical services. Rising disposable incomes and government investments in healthcare drive up demand for diagnostic tests, especially those for influenza.
As Asia Pacific countries invest more in healthcare infrastructure and services, healthcare spending rises. This increasing investment promotes the use of innovative diagnostic technologies, hence driving growth in the influenza diagnostics market.
The Asia Pacific region's public is becoming more aware of infectious diseases, particularly influenza. Increased awareness generates more demand for diagnostic testing, particularly during influenza seasons, which contributes to market growth.
The Asia Pacific region has a vast and fast expanding population, especially in cities. Increased population density raises the risk of influenza transmission, driving up need for diagnostic tests to monitor and manage illness spread.
Countries in the Asia Pacific area are increasingly adopting innovative healthcare technologies, such as telemedicine platforms and point-of-care diagnostic devices. These technologies provide access to healthcare services and enable faster detection and treatment of influenza, resulting in market growth.
The COVID-19 pandemic has expedited the deployment of telehealth platforms throughout the Asia Pacific. The integration of influenza diagnostic tests with telehealth services allows for remote consultations and testing, increasing access to diagnostic services and driving market growth.
The Global Influenza Diagnostics Market is segmented based on Product, End-User, Test Type, And Geography.
Based on Product, the market is segmented into test kits and reagents, instruments, and others. Test kits and reagents dominate the Influenza Diagnostics Market, accounting for almost 60% of the total market share. This is due to a variety of causes, including its widespread availability through pharmacies, clinics, and internet sellers, frequently without the requirement for a prescription. These test kits are popular because they are simple to use; many are developed for point-of-care settings and require little training to administer. Furthermore, their low cost in comparison to other instruments makes them affordable to those with a variety of budgets. Given the importance of early influenza detection, these kits meet a significant need by offering a quick and accessible testing alternative. Furthermore, their versatility enables them to serve both healthcare professionals and those seeking self-testing choices at home.
Based on End-users, the Global Influenza Diagnostics Market has been segmented into diagnostics laboratories, hospitals & clinics, and others. Hospitals and Clinics dominate the Influenza Diagnostics Market, owing to a number of important considerations. For starters, hospitals face a larger disease load, with a greater number of patients presenting with influenza-like symptoms, demanding frequent testing to ensure correct diagnosis and treatment decisions. Second, hospitals often have advanced testing capabilities, including access to a wide range of diagnostic tools and sophisticated apparatus, allowing for more precise and extensive testing procedures. Furthermore, hospitals have strong infrastructure and specialized people, such as dedicated laboratory facilities and trained experts who can successfully handle and interpret influenza diagnostic tests. Given the importance of prompt and correct diagnosis in patient treatment, hospitals prioritize diagnostic accuracy and efficiency. Furthermore, hospitals play an important role in public health surveillance by reporting influenza cases, relying on dependable diagnostic results to inform public health interventions and strategies.
Based on Test Type, the Global Influenza Diagnostics Market is classified into traditional tests and molecular diagnostic assay. While the Influenza Diagnostics Market is moving, traditional tests, such as Rapid Influenza Diagnostic Tests (RIDTs), continue to hold the majority share, accounting for around 66.7%. This is mostly due to various variables. First and foremost, traditional tests are less expensive than molecular assays, making them more accessible in a variety of healthcare settings. Furthermore, many traditional tests, particularly RIDTs, provide speedy results at the point of care, allowing for timely treatment options. Furthermore, their ease of use, with no administration training, makes them appropriate for widespread deployment in clinics and even self-testing. Given the high prevalence of influenza A and B, standard tests can detect the most common influenza strains, meeting a major amount of diagnostic needs. Moreover, the frequent use of traditional testing over a longer period has solidified their position in healthcare settings, contributing to their continued dominance in the market.
Based on Geography, the Global Influenza Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is significantly dominating the influenza diagnostics market and is expected to continue its growth throughout the forecast period, owing to several variables. North America has a well-developed healthcare infrastructure that includes cutting-edge medical facilities, advanced laboratories, and a qualified workforce. This infrastructure facilitates the effective diagnosis and management of influenza patients, which contributes to the region's market leadership. The region is home to leading pharmaceutical businesses, diagnostic manufacturers, and research organizations focused on improving influenza diagnostics. Ongoing research and development activities are aimed at inventing new diagnostic technologies, improving test accuracy, and increasing testing accessibility, thereby cementing North America's position as a dominating market participant.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.